News nuovi farmaci in Inglese

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study


Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes


Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")


Antivirali ad azione diretta, livelli di RNA non predittivi di risposta al trattamento


Coinfezione HIV-HCV: i dati di Harvoni® (ledipasvir/sofosbuvir )


Effects of Sustained Virological Response on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection


Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study


All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study


Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1−6 HCV Infection


An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin


Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post- Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study


C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results)


Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation


Turquoise-ii: regimens of abt-450/r/ombitasvir and dasabuvir with ribavirin achieve high svr12 rates in hcv genotype 1-infected patients with cirrhosis, regardless of baseline characteristics


HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management


Non-Type 1 HCV Predicts Sustained Virologic Response in Cancer Survivors


Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis


Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")


Costo efficacia dei test non invasivi per decidere il trattamento dei pazienti con epatite C cronica Cost-Effectiveness of Noninvasive Liver Fibrosis Tests


Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)


Pagina:  1  2  3  4  5

Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!